<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cold Spring Harb Perspect Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Cold Spring Harb Perspect Med</journal-id>
<journal-id journal-id-type="publisher-id">cshperspectmed</journal-id>
<journal-id journal-id-type="hwp">cshperspectmed</journal-id>
<journal-title-group>
<journal-title>Cold Spring Harbor Perspectives in Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2157-1422</issn>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
<publisher-loc>Cold Spring Harbor, New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29311123</article-id>
<article-id pub-id-type="pmc">5983160</article-id>
<article-id pub-id-type="doi">10.1101/cshperspect.a029017</article-id>
<article-id pub-id-type="publisher-id">a029017</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>097</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Perspectives</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Gut Microbiome and Multiple Sclerosis</article-title>
<alt-title alt-title-type="left-running">J. Ochoa-Repáraz et al.</alt-title>
<alt-title alt-title-type="right-running">Gut Microbiome and Multiple Sclerosis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ochoa-Repáraz</surname>
<given-names>Javier</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kirby</surname>
<given-names>Trevor O.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kasper</surname>
<given-names>Lloyd H.</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label>Department of Biology, Eastern Washington University, Cheney, Washington 99004</aff>
<aff id="af2"><label>2</label>Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire 03756</aff>
<author-notes>
<corresp>
<italic>Correspondence:</italic>
<email>jochoareparaz@ewu.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>6</month>
<year>2018</year>
</pub-date>
<volume>8</volume>
<issue>6</issue>
<elocation-id>a029017</elocation-id>
<permissions>
<copyright-statement>
<ext-link ext-link-type="uri" xlink:href="http://www.perspectivesinmedicine.org/site/misc/terms.xhtml">Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved</ext-link>
</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="cshperspectmed-MSC-a029017.pdf"></self-uri>
<abstract>
<p>The microbiome can be defined as the sum of the microbial and host’s genome. Recent information regarding this complex organ suggests that in animal models of multiple sclerosis (MS), the composition of the gut microbiome can be altered, giving rise to both the effector and regulatory phases of central nervous system (CNS) demyelination. Experimental findings during the past decade in animal models of MS have provided clear evidence for the significant role of gut microbes in both the effector and regulatory phase of this condition. There is mounting evidence in preliminary human studies suggesting that a dysbiotic MS gut microbiome could affect disease progression. We propose considering the gut microbiome as a key organ for the regulation of tolerance mechanisms and speculate that the gut microbiome is the major environmental risk factor for CNS demyelinating disease. Accordingly, we hypothesize that intervention of the gut microbiome could result in safer novel therapeutic strategies to treat MS.</p>
</abstract>
<counts>
<page-count count="15"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>